Scarica l'app Stockscreener
54.21
0.13%
0.07
Pre-mercato:
55.99
1.78
+3.28%
Precedente Chiudi:
$54.14
Aprire:
$54.14
Volume 24 ore:
873.74K
Relative Volume:
1.37
Capitalizzazione di mercato:
$2.29B
Reddito:
$17.39M
Utile/perdita netta:
$-135.89M
Rapporto P/E:
-11.68
EPS:
-4.64
Flusso di cassa netto:
$-123.00M
1 W Prestazione:
+13.29%
1M Prestazione:
+33.59%
6M Prestazione:
+7.95%
1 anno Prestazione:
+101.08%
Intervallo 1D:
$53.18
$55.07
Intervallo di 1 settimana:
$47.60
$55.07
Portata 52W:
$24.95
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Nome
Tarsus Pharmaceuticals Inc
Settore
Industria
Telefono
(949) 409-9820
Indirizzo
15440 LAGUNA CANYON ROAD, IRVINE
Confronta TARS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
54.21 | 2.29B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-27 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-20 | Iniziato | Goldman | Neutral |
| 2023-07-18 | Iniziato | William Blair | Outperform |
| 2023-05-18 | Iniziato | Guggenheim | Buy |
| 2022-08-01 | Iniziato | Barclays | Overweight |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-23 | Iniziato | Oppenheimer | Outperform |
| 2020-11-10 | Iniziato | BofA Securities | Buy |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-11-10 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Combining price and volume data for Tarsus Pharmaceuticals Inc.Market Risk Summary & Proven Capital Preservation Methods - Newser
Visualizing Tarsus Pharmaceuticals Inc. stock with heatmapsQuarterly Portfolio Summary & Growth-Oriented Investment Plans - Newser
Applying Elliott Wave Theory to Tarsus Pharmaceuticals Inc.July 2025 Trade Ideas & Technical Entry and Exit Alerts - Newser
Evaluating Tarsus Pharmaceuticals Inc. with trendline analysisQuarterly Profit Review & Entry Point Confirmation Signals - Newser
Can machine learning forecast Tarsus Pharmaceuticals Inc. recoveryTrade Exit Summary & Reliable Intraday Trade Alerts - Newser
Top Risks to Consider Before Buying Tarsus Pharmaceuticals Inc. StockJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Why Tarsus Pharmaceuticals Inc. is moving todayPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - Newser
How Tarsus Pharmaceuticals Inc. stock performs during market volatilityInflation Watch & Verified Stock Trade Ideas - Newser
Volume spikes in Tarsus Pharmaceuticals Inc. stock – what they meanJuly 2025 Momentum & Verified Momentum Watchlists - Newser
Can technical indicators confirm Tarsus Pharmaceuticals Inc.’s reversal2025 Dividend Review & Safe Capital Investment Plans - Newser
Using Python tools to backtest Tarsus Pharmaceuticals Inc. strategies - Newser
Reversal indicators forming on Tarsus Pharmaceuticals Inc. stockQuarterly Trade Summary & Weekly Top Gainers Trade List - Newser
How to build a custom watchlist for Tarsus Pharmaceuticals Inc.Weekly Volume Report & AI Driven Price Predictions - Newser
How hedge fund analytics apply to Tarsus Pharmaceuticals Inc. stock2025 Analyst Calls & Fast Moving Market Watchlists - Newser
Tools to assess Tarsus Pharmaceuticals Inc.’s risk profileWeekly Stock Summary & Community Driven Trade Alerts - Newser
Tarsus Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Trend Summary & High Accuracy Swing Trade Signals - Newser
Published on: 2025-08-14 04:24:26 - beatles.ru
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionMarket Trend Summary & Accurate Trade Setup Notifications - Newser
Pattern recognition hints at Tarsus Pharmaceuticals Inc. upsideWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Grading 2 Pharma Stocks That Are Heating Up as Large-Cap Rivals Falter - TheStreet Pro
Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87 - Investor's Business Daily
Tarsus Pharmaceuticals Q2 2025: Key Contradictions on XDEMVY's Market Potential, Discount Strategies, and Seasonal Sales Trends - AInvest
Published on: 2025-08-10 23:25:21 - Newser
Detecting support and resistance levels for Tarsus Pharmaceuticals Inc.Market Timing Strategy with Technical Filters - Newser
Tarsus Pharmaceuticals’ Earnings Call Highlights XDEMVY Success - TipRanks
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $75 - 富途牛牛
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals shares fall 7.01% after-hours following Q2 2025 earnings call. - AInvest
Tarsus Pharmaceuticals Reports Record Q2 Net Sales of $102.66M, Exceeding Consensus - AInvest
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Tarsus Pharmaceuticals: Strong Sales Growth and Strategic Initiatives Drive Buy Rating - TipRanks
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Envestnet Asset Management Inc. - Defense World
Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum - MSN
Tarsus Pharmaceuticals: Scaling a High-Growth Eye Care Platform with a Diversified Pipeline and Strong Commercial Execution - AInvest
Tarsus Pharmaceuticals Sees 95,000-100,000 Bottles Target for Q3 2025 Amid Record-Breaking Sales - AInvest
Tarsus Pharmaceuticals Reports Record Sales Growth - TipRanks
Transcript : Tarsus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Tarsus 2025 Q2 Earnings Loss Narrows as Revenue Surges 151.5% - AInvest
Tarsus Pharmaceuticals : Second Quarter 2025 Earnings Presentation - MarketScreener
Tarsus Pharmaceuticals Q2 revenue beats expectations - MarketScreener
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Globe and Mail
Tarsus Pharmaceuticals Reports Record $102.7 Million in Quarterly Net Product Sales of XDEMVY, a 152% Increase Year Over Year - Quiver Quantitative
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements - Yahoo Finance
Published on: 2025-08-04 16:33:09 - beatles.ru
How does Tarsus Pharmaceuticals Inc. compare to its industry peersProven strategies for superior portfolio growth - Jammu Links News
What are the technical indicators suggesting about Tarsus Pharmaceuticals Inc.Maximize gains with timely market signals - Jammu Links News
Is Tarsus Pharmaceuticals Inc. stock overvalued or undervaluedRapid growth opportunities - Jammu Links News
Why is Tarsus Pharmaceuticals Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - Jammu Links News
Is Tarsus Pharmaceuticals Inc. a good long term investmentUnlock powerful stock screening for profits - Jammu Links News
Is it the right time to buy Tarsus Pharmaceuticals Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
Tarsus Pharmaceuticals Inc Azioni (TARS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):